论文部分内容阅读
北京红林制药有限公司是美国海星国际集团歌戈药业公司(GoeGoe Pharmaceutical Co.)投资兴建的现代化GMP制药企业,也是首批通过最新版GMP(2010年版)的制药企业,注册资金近亿元,拥有先进的缓控释技术,“国家高新技术企业”。公司生产基地座落于北京市怀柔区雁栖经济开发区。目前公司在研新药项目近十项,其中缓控释产品占70%以上。已批准二类新药1个,三类新药2个,四类新药1个。公司已注册美国控释技术专利4项、中国控释技术专利5项,并拥有进
Beijing Honglin Pharmaceutical Co., Ltd. is a modern GMP pharmaceutical enterprise invested by GoeGoe Pharmaceutical Co., a starfish international group in the United States. It is also one of the first batch of pharmaceutical companies to pass the latest version of GMP (2010 Edition) with a registered capital of nearly 100 million yuan , With advanced slow control technology, “national high-tech enterprises ”. Company production base is located in Huairou District of Beijing Yanqi Economic Development Zone. At present, the company is investigating nearly 10 new drug projects, of which slow release products account for more than 70%. Two new drugs have been approved, two new drugs of three categories and one new drug of four categories. The company has registered 4 US controlled release technology patents and 5 controlled release technology patents in China,